FDA Accepts Final Section of NDA Filing for LUCASSIN(R)
... (terlipressin for injection) for the treatment of hepatorenal syndrome (HRS) Type 1. The filing was completed ... (R) (terlipressin), for the treatment of hepatorenal syndrome (HRS) Type 1. About Ikaria ... is under review by the FDA for the treatment of hepatorenal syndrome Type 1. Ikaria is headquartered in ...Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics
... - No Currently Approved Drugs to Treat hepatorenal Syndrome Type 1 in U.S. ... approval for LUCASSIN for the treatment of hepatorenal syndrome (HRS) Type 1. LUCASSIN has been ... LUCASSIN(R) (terlipressin), for the treatment of hepatorenal syndrome (HRS) Type 1. Contact: Samina Bari ...Intensive Care Patients More At Risk From Kidney Failure
... death included use of vasopressors (drugs that produce a rise in blood pressure), mechanical ventilation, septic shock, cardiogenic shock, and hepatorenal syndrome (kidney failure combined with severe liver disease). The researchers had conducted a multinational, multicenter, prospective, ...Ikaria(R) Named Private Company of the Year by New Jersey Technology Council
... sulfide. Recently, Ikaria acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in ...IKARIA(R) to In-License BioLineRx's BL-1040
... and hydrogen sulfide. Ikaria also acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in ...Ikaria(R) to Present at 27th Annual JPMorgan Healthcare Conference
... sulfide. Recently, Ikaria acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in ...